Adicet Bio Q1 2025 Earnings Report

Adicet Bio EPS Results

• Actual EPS: -$0.31
• Consensus EPS: -$0.34
• Beat/Miss: Beat by +$0.03
• One Year Ago EPS: N/A

Adicet Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Adicet Bio Announcement Details

• Quarter: Q1 2025
• Date: 5/6/2025
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 6, 2025
• Conference Call Time: 4:00PM ET

Adicet Bio (NASDAQ:ACET) is a clinical-stage biotechnology company focused on the development of allogeneic gamma delta (γδ) T-cell therapies for the treatment of cancer. By harnessing the unique properties of γδ T cells, which possess innate tumor-recognition and rapid cytotoxic activity, the company aims to create off-the-shelf cell therapies that can be manufactured at scale and administered without the need for individualized patient cell collection. Adicet’s proprietary Trio platform combines engineered T-cell receptor components with targeted binding domains to enhance specificity and persistence in solid and liquid tumor settings.

The company’s lead product candidate, ADI-001, is designed to target CD20-expressing hematological malignancies and is currently advancing through early-stage clinical trials in the United States. In parallel, Adicet is developing ADI-002, an investigational gamma delta T-cell therapy directed against solid tumor antigens, with preclinical studies demonstrating favorable safety and tumor-infiltration properties. Both programs leverage a modular manufacturing process intended to optimize consistency and reduce production timelines.

Founded in 2019 and headquartered in Cambridge, Massachusetts, Adicet Bio was formerly known as Activate Immune before rebranding to reflect its focus on gamma delta T cells. The company operates a GMP-compliant manufacturing facility in the U.S. and collaborates with academic and industry partners to support translational research and clinical development. Adicet’s global clinical strategy includes trial sites in North America and Europe, underscoring its commitment to broad patient access.

Under the leadership of a management team with deep expertise in cell therapy, immuno-oncology and biopharmaceutical operations, Adicet Bio combines scientific innovation with a scalable business model. Its executive team draws on experience from leading life-science organizations, positioning the company to advance its pipeline and potentially bring novel cell therapies to patients with high unmet medical needs.